Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,608.37 92.10 0.63%
TOPIX 1,178.23 4.86 0.41%
HANG SENG 22,760.24 64.23 0.28%

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.



Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
                         of Repros Therapeutics, Inc.

PR Newswire

NEW YORK, Oct. 23, 2013

NEW YORK, Oct. 23, 2013 /PRNewswire/ -- Attorney Advertising-- Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Repros Therapeutics, Inc. ("Repros" or the
"Company") (NasdaqCM: RPRX).  Such investors are advised to contact Peretz
Bronstein or his Investor Relations coordinator Eitan Kimelman at
info@bgandg.com or 212-697-6484.

The investigation concerns whether Repros and certain of its officers and/or
directors have violated Sections 10(b) and 20(a) of the Securities Exchange
Act of 1934. Shares of Repros fell $7.17 or 30.27% during intraday trading to
trade at $16.52 after the company delayed its filing for marketing approval of
its testosterone replacement Androxal for several months. Repros said it now
expects to file for approval in the fourth quarter of 2014, after it completes
two studies of the drug. It had planned to make its filing in the middle of
2014. The company said the Food and Drug Administration wants a year of study
data on the effects of the highest dose of Androxal. The agency also told
Repros to request a meeting to discuss the studies the company has conducted.
On September 18, 2013, the company disclosed in a press release that it is
"completely satisfied that all data entered into the data base for study
ZA-301 will pass any scrutiny the FDA chooses to apply."

If you are aware of any facts relating to this investigation, or purchased
shares of Repros, you can assist this investigation by contacting Peretz
Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those
who inquire by e-mail are encouraged to include their mailing address, email
and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients.  In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

SOURCE Bronstein, Gewirtz & Grossman, LLC

Website: http://www.bgandg.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement